Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.05 percent. This is a 11.9 percent decrease over losses of $(0.42) per share from the same period last year.